The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...
Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their ...
The drugs treat prostate, breast and blood cancers. About 80,000 people with Medicare Part D coverage used them in a one-year ...
The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.
Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.
The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...
Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated ...
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback